Letteratura scientifica selezionata sul tema "Propranolol"
Cita una fonte nei formati APA, MLA, Chicago, Harvard e in molti altri stili
Consulta la lista di attuali articoli, libri, tesi, atti di convegni e altre fonti scientifiche attinenti al tema "Propranolol".
Accanto a ogni fonte nell'elenco di riferimenti c'è un pulsante "Aggiungi alla bibliografia". Premilo e genereremo automaticamente la citazione bibliografica dell'opera scelta nello stile citazionale di cui hai bisogno: APA, MLA, Harvard, Chicago, Vancouver ecc.
Puoi anche scaricare il testo completo della pubblicazione scientifica nel formato .pdf e leggere online l'abstract (il sommario) dell'opera se è presente nei metadati.
Articoli di riviste sul tema "Propranolol"
Kobeleva, Tatyana A., Alik I. Sichko, Marina I. Popova e Elena M. Shapovalova. "Development and validation of a spectrophotometric method for the analysis of propranolol in a new soft dosage form "Propranozol"". Человек и его здоровье 24, n. 4 (2021): 83–90. http://dx.doi.org/10.21626/vestnik/2021-4/11.
Testo completoLi, Mi, e Yanqin Ji. "Propranolol Inhibits the Growth of Cervical Cancer Cells by Inhibiting Cyclic Guanosine Monophosphate/Protein Kinase G (cGMP/PKG) Pathway". Journal of Biomaterials and Tissue Engineering 12, n. 2 (1 febbraio 2022): 422–26. http://dx.doi.org/10.1166/jbt.2022.2916.
Testo completoSowinski, Kevin M., e Brad S. Burlew. "Impact of CYP2D6 Poor Metabolizer Phenotype on Propranolol Pharmacokinetics and Response". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 17, n. 6 (12 novembre 1997): 1305–10. http://dx.doi.org/10.1002/j.1875-9114.1997.tb03097.x.
Testo completoHurley, Elisa A. "Pharmacotherapy to Blunt Memories of Sexual Violence: What's a Feminist to Think?" Hypatia 25, n. 3 (2010): 527–52. http://dx.doi.org/10.1111/j.1527-2001.2010.01108.x.
Testo completoAlotaibi, Hadil Faris, Haifa Alotaibi, Khaled M. Darwish, El-Sayed Khafagy, Amr S. Abu Lila, Mohamed A. M. Ali, Wael A. H. Hegazy e Samar Zuhair Alshawwa. "The Anti-Virulence Activities of the Antihypertensive Drug Propranolol in Light of Its Anti-Quorum Sensing Effects against Pseudomonas aeruginosa and Serratia marcescens". Biomedicines 11, n. 12 (28 novembre 2023): 3161. http://dx.doi.org/10.3390/biomedicines11123161.
Testo completoKumar, Lalit, e Puneet Utreja. "Oleic Acid Vesicles for Transdermal Delivery of Propranolol Hydrochloride: Development and Characterization". Current Drug Therapy 15, n. 3 (14 ottobre 2020): 238–48. http://dx.doi.org/10.2174/1574885514666190722164119.
Testo completoMiguel-Puga, Adán, Gabriel Villafuerte, Mario Treviño, Emmanuel Ortega-Robles e Oscar Arias-Carrión. "Effect of Propranolol on Motor Cortex Excitability in Essential Tremor: An Exploratory Study". Tremor and Other Hyperkinetic Movements 14 (2 gennaio 2024): 1. http://dx.doi.org/10.5334/tohm.829.
Testo completo&NA;. "Propranolol see Maprotiline/propranolol". Reactions Weekly &NA;, n. 341 (marzo 1991): 10. http://dx.doi.org/10.2165/00128415-199103410-00057.
Testo completoGulzar, G. M., Showkat A. Zargar, M. S. Alai, S. Jalal, Gul Javid, B. A. Khan, Pawan Suri, A. Shah, M. A. Khan e Jaswinder Singh. "Effect of acute administration of propranolol, carvedilol, iso-sorbide dinitrate, “propranolol plus iso-sorbide dinitrate” and “carvedilol plus iso-sorbide dinitrate” on portal venus pressure." JMS SKIMS 16, n. 2 (12 dicembre 2013): 80–85. http://dx.doi.org/10.33883/jms.v16i2.215.
Testo completoLucido, Christopher, W. Miskimins e Paola Vermeer. "Propranolol Promotes Glucose Dependence and Synergizes with Dichloroacetate for Anti-Cancer Activity in HNSCC". Cancers 10, n. 12 (30 novembre 2018): 476. http://dx.doi.org/10.3390/cancers10120476.
Testo completoTesi sul tema "Propranolol"
Lee, Daniel K. "Cellular Targets of Propranolol in Infantile Hemangioma". Thesis, Harvard University, 2013. http://dissertations.umi.com/gsas.harvard:11218.
Testo completoSchill, Thomas [Verfasser], e Jochen [Akademischer Betreuer] Rößler. "Die systemische Therapie infantiler Hämangiome mit Propranolol". Freiburg : Universität, 2010. http://d-nb.info/1123466033/34.
Testo completoKhoury, Rayana Duarte. "O estresse crônico e a via de sinalização adrenérgica no desenvolvimento da lesão periapical /". São José dos Campos, 2017. http://hdl.handle.net/11449/152533.
Testo completoCoorientadora: Renata Falchete do Prado
Banca: Eduardo Bresciani
Banca: Mariella Vieira Pereira Leão
Resumo: Os objetivos deste estudo são: 1) Esclarecer a possível associação entre o estresse crônico e a estimulação do Sistema Nervoso Simpático (SNS) e investigar sua interferência no desenvolvimento e progressão da lesão periapical; 2) Avaliar a quantidade de receptores para os neurotransmissores na região periapical; 3) Elucidar uma via farmacológica de modulação inflamatória através do uso de bloqueadores adrenérgicos. Trinta e dois ratos Wistar foram submetidos à modelo animal de lesão periapical através da exposição da cavidade pulpar e em seguida foram aleatoriamente divididos em 4 grupos: sem estresse (NS); estresse + solução salina (SS); estresse + β-bloqueador (Sβ); estresse + α-bloqueador (Sα). Os grupos SS, Sβ e Sα foram submetidos à modelo animal de estresse crônico durante 28 dias e receberam injeções diárias de solução salina, propranolol (β bloqueador adrenérgico) e fentolamina (α bloqueador adrenérgico), respectivamente. Após 28 dias os animais foram eutanasiados e procedeu-se as seguintes análises: a) dos níveis séricos de corticosterona através de Radioimunoensaio; b) histomorfométrica por coloração com hematoxilina e eosina; c) da estrutura óssea periapical através de microtomografia computadorizada (micro-CT); d) expressão de receptores β e α adrenérgicos; e) da atividade osteoclástica através de histoquímica para fosfatase ácida resistente ao tartarato (TRAP). Os resultados obtidos mostram um aumento do nível sérico de corticosterona dos animais do grupo SS send... (Resumo completo, clicar acesso eletrônico abaixo)
Abstract: The objectives of this study are: 1) To clarify the possible association between chronic stress (CS) and stimulation of the Sympathetic Nervous System (SNS) and to investigate its interference in the development and progression of periapical lesion; 2) To evaluate the amount of receptors for neurotransmitters in the periapical region; 3) To elucidate a pharmacological pathway of inflammatory modulation through the use of adrenergic blockers. Thirty- two Wistar rats were submitted to animal model of periapical lesion through exposure of the pulp cavity and were then randomly divided into 4 groups: no stress (NS); stress + saline solution (SS); stress + β-blocker (Sβ); stress + α-blocker (Sα). The SS, Sβ and Sα groups were submitted to animal model of CS for 28 days and received daily injections of saline solution, propranolol (β blocker adrenergic) and phentolamine (α adrenergic blocker), respectively. After 28 days the animals were euthanized and the following analysis were carried out: a) serum corticosterone levels through Radioimmunoassay; b) histomorphometric by staining with hematoxylin and eosin; c) periapical bone structure through micro computed tomography; d) expression of β and α adrenergic receptors; e) osteoclast activity by histochemistry for tartrate resistant acid phosphatase (TRAP). The results obtained show an increase in the seric corticosterone level of the animals of the SS group being statistically significant compared to the NS group animals (without str... (Complete abstract click electronic access below)
Mestre
Meimoun, Laurence. "Les migraines : comparaison des effets thérapeutiques du propranolol avec ceux d'autres antimigraineux". Paris 5, 1994. http://www.theses.fr/1994PA05P163.
Testo completoOttilie, Henry. "Einfluß von Propranolol auf den Fastenstoffwechsel des Schafes". Doctoral thesis, Universitätsbibliothek Leipzig, 2004. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-36675.
Testo completoThe treatment of the fatty liver disease is world-wide regarded as unsatisfactory, so that death of the affected ruminants is partly unavoidable. The administration of beta receptor blockers in such cases has not found its way into veterinary medicine until now. In this study, the effects of a nonspecific blockade of the beta adrenoceptors on lipolysis, clinical and hematological parameters as well as on the metabolism of the liver, proteins and minerals in fasting sheep were therefore tested. Especially, the effect of a Propranolol administration on the lipolysis in the early stage of fasting was examined. During a three-day period of food deprivation, 15 female, clinically healthy and non-pregnant sheep (Merino-Fleisch) were given 0.5 or 1 mg Propranolol/kg body weight per day via a continuous infusion with two interruptions of eight hours. During the experiment, pulse, respiration rate, body temperature and rumen activity were checked. The serum concentrations of glucose, FFA, bilirubin, beta-hydroxybutyrate, potassium, sodium, magnesium, total protein and albumin were controlled by repeatedly taking blood samples from the vena jugularis externa. The activity of the enzymes GLDH and AST were determined to check the liver function. The effect of the beta-receptor antagonist Propranolol on the hematological parameters was checked by examining the WBC, RBC, the hemoglobin concentrations and the packed cell volume. All test groups showed significant decrease in body weigth of up to 9.8 %, due to the three-day food deprivation. Even within the first 48 hours of food deprivation, rumen motility of all animals was decreasing significantly. Those sheep which received 1 mg Propranolol/kg body weight per day showed the strongest decrease in rumen activity. Pulse and respiration rate, the concentrations of potassium, sodium, magnesium, total protein and albumin as well as the activity of GLDH and AST in blood serum remained without significant changes during the experiment. Neither the sheep of the control group nor those of the experimental groups showed any influence on the hematological parameters. While the blood glucose concentration tended to be lower during the food deprivation in all groups, the concentrations of FFA, bilirubin and beta-hydroxybutyrate in blood serum were increasing. Thus, the changes of FFA, bilirubin and beta-hydroxybutyrate concentrations in the control group showed the typical characteristics of fasting metabolism. These absolute increases in concentrations were significantly lower in both experimental groups than those in the control group. With regard to the levels reached and compared to the control group, a smaller load of energy and liver metabolism could be determined in the experimental groups. The transition from the first to the second stage of the fasting metabolism in all groups (but especially in the experimental groups) was clearly discernible in the rises of body temperature and in the stronger increases of the FFA concentrations approximately 48 hours after the experiment started. The special clinical and diagnostic importance of the FFA concentration was indicated in an earlier and stronger change of the FFA concentration in the blood serum, compared to the changes of bilirubin and beta-hydroxybutyrate. As early as 24 hours after the beginning of the fasting, a significant rise of the FFA concentration in comparison to the initial concentration could be proved. In contrast to the control group the two experimental groups showed a smaller increase in the FFA concentration. All groups reached their maxima of FFA concentration 48 hours after the beginning of the experiment. Afterwards FFA concentrations in the two experimental groups were sinking fast and significantly by 44.7 % and 63.5 % respectively. In the control group, the decrease of the FFA concentration from the maximum until the end of the experiment was only 8.6 % and thus significantly lower than the comparative results. At the end of the experiment, significant differences in FFA concentrations between all groups could be proved. So, it can be assumed that there is a dose-dependent effect of Propranolol on the FFA release from the bodyŽs own fat depots. The FFA concentration in the control group was decreasing during the NaCl-infusion. This could be due to NaClŽs influence on the pH value of the blood. The reduction of the pH causes a decreasing rate of the lipolysis. The strong rise of FFA concentration between the infusion in the control group, lead to significantly higher results compared to the experimental groups. The changes of total and direct reacting bilirubin in the control group were higher than in the experimental groups. While maximum concentrations of total bilirubin acid in the experimental groups (which got 0.5 and 1 mg Propranolol/kg body weigth per day respectively) could be determined 48 hours after the experimentŽs start, maximum concentrations in the control group could be found only 56 hours after beginning of the fasting. Beta-hydroxybutyrate concentrations in the experimental groups were also lower than in the control group. These differences between the groups indicate a smaller strain of the liver in the experimental groups. The lowest beta-hydroxybutyrate concentrations could be proved in the experimental group with a dose of 1 mg Propranolol/kg body weight per day. In this group, the maximum beta-hydroxybutyrate concentration was reached 32 hours after the beginning of the fasting. These results suggest that by the administration of Propranolol at doses of 0.5 mg and 1 mg/kg body weigth per day respectively it is possible to inhibit the lipolysis within the first 64 hours after a food deprivation without effecting the hematological parameters. Particularly, the comparable increases in FFA concentrations in the experimental and control groups between the infusions indicate a direct effect of the beta-adrenergic antagonist on the lipolysis during the infusions. The changes of bilirubin and beta-hydroxybutyrate concentrations in the experimental groups were smaller than those in the control group. This suggests a smaller strain on the energy and liver metabolism in the experimental groups compared to the control group. The nonsignificant changes of the activity of GLDH and AST indicate no negative influence on the liver function after applicating Propranolol. The stronger reduction of rumen motility and the smaller increase of the FFA concentration in the group with 1 mg Propranolol/kg body weigth per day compared to the group with 0.5 mg Propranolol/kg body weigth per day shows the dose-dependent effect of Propranolol. The application of Propranolol at a dose of 0.5 mg or 1 mg/kg body weigth per day is a suitable method to early inhibit fasting-induced lipolysis in sheep
Song, Karine. "Etudes pharmacotoxicologiques du propranolol et de ses enantiomères". Paris 5, 1997. http://www.theses.fr/1997PA05P126.
Testo completoMartin, Paul D. "The application of molecular imprinted polymers to the solid phase extraction of drugs". Thesis, Keele University, 2002. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.250426.
Testo completoОвечкін, Денис Вячеславович, Денис Вячеславович Овечкин, Denys Viacheslavovych Ovechkin, Василь Васильович Леонов, Василий Васильевич Леонов, Vasyl Vasylovych Leonov, C. Ngetich e Z. Adigun. "Propranolol-resistant infantile hemangiomas: the analysis of 2 cases". Thesis, Sumy State University, 2016. http://essuir.sumdu.edu.ua/handle/123456789/48495.
Testo completoYim, Júnior Alberto [UNIFESP]. "Efeitos da infusão intra-amigdalar do inibidor de síntese protéica anisomicina e da administração sistêmica do propranolol após a evocação sobre a expressão de uma preferência condicionada ao lugar induzida pela morfina". Universidade Federal de São Paulo (UNIFESP), 2007. http://repositorio.unifesp.br/handle/11600/23506.
Testo completoConselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq)
Diversos estudos tem mostrado que memorias aversivas antigas, ja consolidadas, quando reativadas, retomam em um estado fragil, necessitando de uma nova rodada de consolidacao para que ela tome-se novamente estavel. Este fenomeno e denominado de reconsolidacao, sendo dependente tanto da sintese proteica quanto do sistema noradrenergico. A tarefa da preferencia condicionada pelo lugar e um tipo de condicionamento pavloviano no qual o animal aprende a associar pistas ambientais com uma recompensa, sendo amplamente utilizado para o estudo das propriedades recompensadoras dos alimentos e das drogas de abuso. A amigdala basolateral e uma estrutura relacionada com o aprendizado aversivo, como o condicionamento do medo ao som e ao contexto. Esta estrutura esta tambem envolvida com o aprendizado apetitivo, incluindo a preferencia condicionada pelo lugar. Diversos trabalhos com farmacologia, inativacao e lesao tem mostrado que esta estrutura esta envolvida com a aquisicao, a consolidacao, a expressao e o restabelecimento dessa tarefa. Como a infusao de um inibidor de sintese proteica (anisomicina) na amigdala basolateral bloqueou a reconsolidacao em uma tarefa aversiva, e como esta estrutura tambem esta envolvida na expressao da preferencia condicionada pelo lugar, a primeira parte deste estudo investigou se a infusao da anisomicina bloqueou a reconsolidacao desta tarefa. Os resultados deste estudo mostraram que a anisomicina, quando infundida na amigdala basolateral imediatamente apos a reativacao(teste), nao prejudicou o desempenho dos animais em um teste posterior, indicando que nao houve reconsolidacao dependente de sintese proteica nesta estrutura para a tarefa de preferencia condicionada pelo lugar. A segunda parte deste estudo teve por objetivo verificar se o propranolol, um antagonista β-noradrenergico, quando injetado sistemicamente, bloquearia a reconsolidacao da tarefa de preferencia condicinada pelo lugar induzida pela morfina, uma vez que diversos estudos verificaram que essa droga bloqueia a reconsolidacao, tanto de tarefas aversivas, quanto de apetitivas. Novamente, a adminsitracao sistemica do propranolol apos a reativacao(teste), nao prejudicou o desempenho dos animais, sugerindo que nao houve reconsolidacao dependente do sistema noradrenergico na tarefa de preferencia pelo lugar desta tarefa. Os resultados deste estudo mostraram que a anisomicina, quando infundida na amigdala basolateral imediatamente apos a reativacao (teste), nao prejudicou o desempenho dos animais em um teste posterior, indicando que nao houve reconsolidacao dependente de sintese proteica nesta estrutura para a tarefa de preferencia condicionada pelo lugar. A segunda parte deste estudo teve por objetivo verificar se o propranolol, um antagonista β-noradrenergico, quando injetado sistemicamente, bloquearia a reconsolidacao da tarefa de preferencia condicionada pelo lugar induzida pela morfina, uma vez que diversos estudos verificaram que essa droga bloqueia a reconsolidacao, tanto de tarefas aversivas, quanto de apetitivas. Novamente, a administracao sistemica do propranolol apos a reativacao (teste), nao prejudicou o desempenho dos animais, sugerindo que nao houve reconsolidacao dependente do sistema noradrenergico na tarefa de preferencia pelo lugar
BV UNIFESP: Teses e dissertações
Prey, Sorilla. "Propranolol dans les hemangiomes infantiles : tolérance et identification des voies thérapeutiques". Thesis, Bordeaux, 2014. http://www.theses.fr/2014BORD0342.
Testo completoCapillary infantile haemangioma (IH) is a common benign vascular tumour of infants. Severe forms are treated since 2008 by propranolol. However, its dramatic efficacy remains until now unexplained.The first part of my thesis is a safety study of children treated with propranolol as part of the French Compassionate Use Program. The prospective vigilance database, including 922 children, confirmed the safety of propranolol among the paediatric patients, and highlighted the circumstances at risk of complications.The second part is a study of adrenergic signaling in IH tissues. First, we identified by immunofluorescence the expression of beta-adrenergic receptors on IH cells. We observed a strong expression of ADRB2 on mast cells, and a moderate ADRB1 and 2 expression on vessels. This expression pattern was the same regardless of the degree of involution of the tumour, and has also been observed on tumour vascular controls which did not respond to propranolol. We therefore hypothesized that ADRB receptors may be activated in proliferative IH. We indeed detected the expression of catecholamine synthesis enzymes and of neuro-endocrine markers on pericytes in paraffin-embedded tissues, and also in IH pericytes in culture. We also detected HIF1-alpha overexpression and therefore explored propranolol effect during hypoxia. Propranolol had no effect on cell proliferation, but reduced hypoxia-induced secretion of VEGF-A
Libri sul tema "Propranolol"
J, Delic, e Great Britain. Health and Safety Executive., a cura di. Propranolol: Criteria document for an occupational exposure limit. Sudbury: HSE Books, 1995.
Cerca il testo completoParadiso, Frances Lori. The central nervous system effects and pharmacokinetics of propranolol enantiomers. Ottawa: National Library of Canada = Bibliothèque nationale du Canada, 1993.
Cerca il testo completoAngrini, Manar A. Effect of propranolol and other 5-HT antagonists of motivated and emotional behaviour. [S.l: The Author], 1997.
Cerca il testo completoHassounah, Ahmed. The effect of propranolol on renal prostaglandin-E2, the reninangiotensin and kidney function in rabbit. Salford: University of Salford, 1990.
Cerca il testo completoMathieu, Charlotte. Phase III-Studie zur Wirksamkeit und Sicherheit von oralem Propranolol bei Säuglingen mit schweren, proliferierenden Hämangiomen. [S.l: s.n.], 2013.
Cerca il testo completoPett, Burkhard. Der Einfluss von Propranolol auf die Dosiswirkungskurven der kardiovaskulären Effekte von Isoprenalin in Abhängigkeit von der dosis- und zeitabhängigen Besetzung von [beta]₁- und [beta]₂-Adrenozeptoren. [s.l.]: [s.n.], 1987.
Cerca il testo completoHansen, Matthias. Monotherapie der Hyperthyreose mit R-Propranolol. 1995.
Cerca il testo completoPitschner, Heinz-Friedrich. Zeitwirkungsverlauf und Plasmakonzentrationskinetik von Propranolol und Carteolol beim Menschen. 1986.
Cerca il testo completoGraf, Kai-Ivo. Einfluss von Propranolol auf [beta]₂-adrenerge Rezeptorendichten und -funktion. 1995.
Cerca il testo completoPuljevic, Mislav. Propranolol: Medical Uses, Mechanisms of Action and Potential Adverse Effects. Nova Science Publishers, Incorporated, 2015.
Cerca il testo completoCapitoli di libri sul tema "Propranolol"
Maxwell, Robert A., e Shohreh B. Eckhardt. "Propranolol". In Drug Discovery, 3–18. Totowa, NJ: Humana Press, 1990. http://dx.doi.org/10.1007/978-1-4612-0469-5_1.
Testo completoMcAllister-Williams, R. Hamish, Daniel Bertrand, Hans Rollema, Raymond S. Hurst, Linda P. Spear, Tim C. Kirkham, Thomas Steckler et al. "Propranolol". In Encyclopedia of Psychopharmacology, 1074–75. Berlin, Heidelberg: Springer Berlin Heidelberg, 2010. http://dx.doi.org/10.1007/978-3-540-68706-1_1846.
Testo completoBeyer, Karl-Heinz. "Propranolol". In Biotransformation der Arzneimittel, 480–82. Berlin, Heidelberg: Springer Berlin Heidelberg, 1990. http://dx.doi.org/10.1007/978-3-642-74386-3_275.
Testo completoWilson, John Fawcett. "Propranolol". In The Immunoassay Kit Directory, 1604–5. Dordrecht: Springer Netherlands, 1995. http://dx.doi.org/10.1007/978-94-011-0679-5_45.
Testo completoBaron, Susannah. "Propranolol". In Handbook of Systemic Drug Treatment in Dermatology, 215–19. 3a ed. London: CRC Press, 2022. http://dx.doi.org/10.1201/9781003016786-31.
Testo completoSchneeweiss, Adam, e Gotthard Schettler. "Propranolol". In Developments in Cardiovascular Medicine, 305–27. Boston, MA: Springer US, 1988. http://dx.doi.org/10.1007/978-1-4613-2063-0_36.
Testo completode Groot, Anton C. "Propranolol". In Monographs In Contact Allergy, 826–27. Boca Raton: CRC Press, 2022. http://dx.doi.org/10.1201/9781003158004-420.
Testo completoPeter, Helga. "Propranolol". In Springer Reference Medizin, 1. Berlin, Heidelberg: Springer Berlin Heidelberg, 2020. http://dx.doi.org/10.1007/978-3-642-54672-3_781-1.
Testo completoFleig, H. A., e G. K. Krieglstein. "(—)-Propranolol in the Isolated Rabbit Iris". In Second European Glaucoma Symposium, Helsinki, May 1984, 111–17. Dordrecht: Springer Netherlands, 1985. http://dx.doi.org/10.1007/978-94-009-5516-5_20.
Testo completoCannell, G. R., A. J. Fletcher, R. H. Mortimer e D. J. Maguire. "Placental Propranolol Metabolism in Normoxia and Hypoxia". In Advances in Experimental Medicine and Biology, 390. Boston, MA: Springer US, 1994. http://dx.doi.org/10.1007/978-1-4615-1875-4_69.
Testo completoAtti di convegni sul tema "Propranolol"
Shi, Juntao. "Propranolol and nifedipine efficacy against hypertension". In International Conference on Biological Engineering and Medical Science (ICBIOMed2022), a cura di Gary Royle e Steven M. Lipkin. SPIE, 2023. http://dx.doi.org/10.1117/12.2669574.
Testo completoRincón, D. A., M. C. Daza e M. Doerr. "Application of the quantum theory of atoms in molecules (QTAIM) to the study of the enzymatic kinetic resolution of propranolol, an amino alcohol with pharmaceutical applications". In VIII Simpósio de Estrutura Eletrônica e Dinâmica Molecular. Universidade de Brasília, 2020. http://dx.doi.org/10.21826/viiiseedmol2020135.
Testo completoZapata-Romero, Gilberto A., Markus Doerr e Martha C. Daza. "Enantioselective lipase-catalyzed O-acylation of (RS)-propranolol: analysis of the hydrogen bonds essential for catalysis". In VIII Simpósio de Estrutura Eletrônica e Dinâmica Molecular. Universidade de Brasília, 2020. http://dx.doi.org/10.21826/viiiseedmol2020131.
Testo completoKevrić, Andrea, e Jelena Roganović. "321 Threatment of infantile hemangiomas with propranolol". In 10th Europaediatrics Congress, Zagreb, Croatia, 7–9 October 2021. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2021. http://dx.doi.org/10.1136/archdischild-2021-europaediatrics.321.
Testo completoHe, Huarui, Georg Uray e Otto S. Wolfbeis. "Enantio-selective optode for the β-blocker propranolol". In Microlithography '91, San Jose,CA, a cura di Robert A. Lieberman e Marek T. Wlodarczyk. SPIE, 1991. http://dx.doi.org/10.1117/12.24805.
Testo completoLI, Xiaojuan, Xiaorui XIE, Jin REN, Liling REN e Jian CAO. "Effects of Propranolol on Osteoclasts Cultured in Vitro". In International Conference on Biological Engineering and Pharmacy 2016 (BEP 2016). Paris, France: Atlantis Press, 2017. http://dx.doi.org/10.2991/bep-16.2017.6.
Testo completoCalderon Barahona, G. M., R. Ali, C. Ortega Giron, W. L. Ng, H. Bobrysheva, E. Calderon Martinez, M. J. Azhar, M. Htoo e A. Atrash. "Beta-Blocked: A Severe Propranolol Overdose Case Report". In American Thoracic Society 2024 International Conference, May 17-22, 2024 - San Diego, CA. American Thoracic Society, 2024. http://dx.doi.org/10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5699.
Testo completoHuang, Dushu, Wei Liu, Lihua Yao, Yong Min, Ruimin Xiao e Yashun Chen. "Enantioseparation of Propranolol Enantiomers Using Hollow Fiber Membrane Contactor". In 2012 International Conference on Biomedical Engineering and Biotechnology (iCBEB). IEEE, 2012. http://dx.doi.org/10.1109/icbeb.2012.197.
Testo completoAbidin, N., D. Jayachandran e P. Shah. "G134 Oral propranolol in the management of infantile haemangiomas". In Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference and exhibition, 13–15 May 2019, ICC, Birmingham, Paediatrics: pathways to a brighter future. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2019. http://dx.doi.org/10.1136/archdischild-2019-rcpch.130.
Testo completoAlonso Peralta, CA, T. Gimenez Poderós, D. Gómez, RM González Franco, B. Rogado Vegas, J. Casanova Vázquez, M. Rioja Carrera et al. "4CPS-135 Perphenazine and propranolol poisoning: a case report". In 25th EAHP Congress, 25th–27th March 2020, Gothenburg, Sweden. British Medical Journal Publishing Group, 2020. http://dx.doi.org/10.1136/ejhpharm-2020-eahpconf.236.
Testo completoRapporti di organizzazioni sul tema "Propranolol"
Aikins, Deane. Using Propranolol to Block Memory Reconsolidation in Female Veterans with PTSD. Fort Belvoir, VA: Defense Technical Information Center, ottobre 2013. http://dx.doi.org/10.21236/ada612332.
Testo completoAikins, Deane. Using Propranolol to Block Memory Reconsolidation in Female Veterans with PTSD. Fort Belvoir, VA: Defense Technical Information Center, ottobre 2010. http://dx.doi.org/10.21236/ada543119.
Testo completoAikins, Deane. Using Propranolol to Block Memory Reconsolidation in Female Veterans with PTSD. Fort Belvoir, VA: Defense Technical Information Center, ottobre 2011. http://dx.doi.org/10.21236/ada561958.
Testo completoMundie, Thomas G., Adolph J. Januszkiewica e Gary R. Ripple. Effects of Epinephrine, Phenoxybenzamine and Propranolol on Maximal Exercise in Sheep. Fort Belvoir, VA: Defense Technical Information Center, ottobre 1992. http://dx.doi.org/10.21236/ada261573.
Testo completoAikins, Deane. Using Propranolol to Block Memory Reconsolidation in Female Veterans with PTSD. Fort Belvoir, VA: Defense Technical Information Center, ottobre 2012. http://dx.doi.org/10.21236/ada598741.
Testo completoAikins, Deane. Using Propranolol to Block Memory Reconsolidation in Female Veterans with PTSD. Fort Belvoir, VA: Defense Technical Information Center, ottobre 2014. http://dx.doi.org/10.21236/ada615056.
Testo completoPitman, Roger K. A Psychophysiologic Study of Weakening Traumatic Combat Memories With Post-Reactivation Propranolol. Fort Belvoir, VA: Defense Technical Information Center, giugno 2008. http://dx.doi.org/10.21236/ada487404.
Testo completoLiu, Xia, Hai-Xu Chen e Bo Chen. Impact of combined propranolol and oxytocin on the process and outcomes of labor: a meta-analysis of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, settembre 2023. http://dx.doi.org/10.37766/inplasy2023.9.0107.
Testo completoPropranolol generally safe in treating childhood haemangioma birthmarks. National Institute for Health Research, gennaio 2017. http://dx.doi.org/10.3310/signal-000363.
Testo completoThe beta-adrenergic receptor blocker and anti-inflammatory drug propranolol mitigates brain cytokine expression in a long-term model of Gulf War Illness (dataset). U.S. Department of Health and Human Services, Public Health Service, Centers for Disease Control and Prevention, National Institute for Occupational Safety and Health, novembre 2021. http://dx.doi.org/10.26616/nioshrd-1024-2021-0.
Testo completo